A Phase 1 interventional study of Tripegfilgrastim in Solid Tumor and Lymphoma, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 6 Years to 19 Years. Per ClinicalTrials.gov, last updated 2019-01-15.
Sponsored by Dong-A ST Co., Ltd. · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing pegfilgrastim in Lymphoma — none open to participants now, 1 under way, none of them phase 3. pegfilgrastim · Lymphoma.
Among the 13 studies testing pegfilgrastim in Lymphoma, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 1, and was the 10th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →None of the 13 studies testing pegfilgrastim in Lymphoma is open now. The open studies under Lymphoma, anywhere →
pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 6 Years to 19 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 2
First in 2000; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 41 across the 13 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 10 most frequent:
Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.
Dong-A ST Co., Ltd. has 1 study filed under Lymphoma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing pegfilgrastim in Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, single ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of Tripegfilgrastim in pediatric solid tumor/lymphoma patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
Drug: Tripegfilgrastim
A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
Drug: Tripegfilgrastim
A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
Drug: Tripegfilgrastim
A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
Drug: Tripegfilgrastim
Also known as: DA-3031
PK parameter
Time to reach Cmax of Tripegfilgrastim \[Tmax\]
Time frame: Day 1(Hour 0) ~ Day 21
PK parameter
Peak plasma concentration of Tripegfilgrastim \[Cmax\]
Time frame: Day 1(Hour 0) ~ Day 21
PK parameter
Area under the plasma concentration of Tripegfilgrastim versus time curve \[AUC\]
Time frame: Day 1(Hour 0) ~ Day 21
PK parameter
Half-life of Tripegfilgrastim \[T1/2\]
Time frame: Day 1(Hour 0) ~ Day 21
PK parameter
The lowest plasma concentration that Tripegfilgrastim reaches before the next dose is administered \[Ctrough\]
Time frame: Day 1(Hour 0) ~ Day 21
PD parameter
Peak plasma concentration of Absolute Neutrophil Count \[ANCmax\]
Time frame: Day 1(Hour 0) ~ Day 14
PD parameter
Area under the plasma concentration of Absolute Neutrophil Count versus time curve \[AUC(ANC)\]
Time frame: Day 1(Hour 0) ~ Day 14
PD parameter
Time to reach Cmax of Absolute Neutrophil Count \[Tmax(ANC)\]
Time frame: Day 1(Hour 0) ~ Day 14
Ran from Oct 2016 to primary completion in Nov 2018, 25 months.
Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 25 months is below that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegfilgrastim